The Iressa Pan-Asia Study (IPASS) showed that EGFR tyrosine kinase inhibitors (EGFR-TKIs) significantly prolonged the survival of NSCLC patients harboring EGFR mutations, a finding that revolutionized the treatment of lung cancer (Chan & Hughes, 2015). This evidence concerns the gene EGFR and non-small cell lung carcinoma.